The site was created by Boehringer Ingelheim after a survey identified knowledge gaps among owners on many health topics ...

Total adverse events of heart failure or all-cause mortality were reduced with empagliflozin, regardless of kidney function.

TOKYO -- German drugmaker Boehringer Ingelheim plans to invest a total of 300 million euros ($346 million) in its plant in Japan from 2023 to 2028 as it moves to make the facility a production base ...

Boehringer Ingelheim launches innovative poultry vaccine in India, offering single-dose protection against major diseases, ...

Boehringer Ingelheim’s Spevigo (spesolimab) has been recommended by the National Institute for Health and Care Excellence ...

What happens when data projects forget the people who use them? A Disconnect. Boehringer Ingelheim turned things around by ...

The agreement will facilitate access to Boehringer Ingelheim’s OpnME platform. The Department of Health – Abu Dhabi has ...